 Acasti Pharma Inc NASDAQ:ACST CVE:ACST FRA:A1PA announced its operating and financial results for the fiscal year ended 31 March, along with an update on its proposed acquisition of Grace Therapeutics. Acasti, a biopharmaceutical innovator, reported a narrower loss from operating activities of 16.4 million, compared to a loss of 24.4 million a year earlier, due mainly to a reduction in expenses. 